Sorafenib,a novel,oral multi-kinase inhibitor,targets on serine/threonine and receptor tyrosine kinases of the tumor cells and vasculature;

• 索拉非尼是首个口服多激酶抑制药,靶向作用于肿瘤细胞和肿瘤血管上的丝氨酸和(或)苏氨酸及受体酪氨酸激酶,阻断信号传导,抑制肿瘤生长。